{
    "clinical_study": {
        "@rank": "126245", 
        "arm_group": {
            "arm_group_label": "Dipeptiven", 
            "arm_group_type": "Experimental", 
            "description": "0.75 g/ kg/ d Dipeptiven ( L- alanine- L- glutamine; 82 mg/ ml L- alanine, 134.6 mg/ ml L- glutamine; Fresenius Kabi, Switzerland) continuous intravenous infusion"
        }, 
        "brief_summary": {
            "textblock": "Severe traumatic brain injury is associated with life-threatening and incapacitating\n      secondary injury.\n\n      Contemporary therapeutic interventions are aimed at preventing and treating secondary\n      damage. In this context, improved cerebral metabolism is an important target in modern\n      neurointensive care.\n\n      The main hypothesis is that continuous intravenous infusion of glutamyl-alanyl dipeptide\n      restores disturbed brain metabolism following severe traumatic brain injury."
        }, 
        "brief_title": "Optimized Therapy in Severe Traumatic Brain Injured Patients", 
        "completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Traumatic Brain Injury", 
            "Coma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients suffering from severe traumatic brain injury and requiring multimodal\n      neuromonitoring during pharmacological coma will receive alanyl-glutamine dipeptide\n      (Dipeptiven) as part of standard clinical nutrition.\n\n      In two groups of patients the influence of different duration of infusion (group 1: 24\n      hours; group 2: 5 days) will be investigated. For this, pharmacokinetic and pharmacodynamic\n      parameters in plasma and brain are determined.\n\n      Increased plasma glutamine and alanine in arterial and jugular venous plasma and in cerebral\n      microdialysates are to reflect efficacy of Dipeptiven infusion.\n\n      Plasma glutamate levels as well as changes in cerebral glutamate, lactate, lactate/pyruvate\n      ratio, intracranial pressure, bispectral index electroencephalography will be measured to\n      exclude potential adverse effects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  severe traumatic brain injury\n\n          -  prolonged pharmacologic coma\n\n          -  multimodal neuromonitoring (microdialysis, ptiO2)\n\n          -  enteral nutrition\n\n        Exclusion Criteria:\n\n          -  patients anticipated to decease within 48 hours\n\n          -  abdominal injury\n\n          -  mass transfusion\n\n          -  renal impairment\n\n          -  hepatic impairment\n\n          -  barbiturate coma\n\n          -  parenteral nutrition\n\n          -  weight below 50 kg\n\n          -  weight above 100 kg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02130674", 
            "org_study_id": "SNF 111782", 
            "secondary_id": "SNF 111782"
        }, 
        "intervention": {
            "arm_group_label": "Dipeptiven", 
            "description": "two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days", 
            "intervention_name": "Dipeptiven", 
            "intervention_type": "Drug", 
            "other_name": "Dipeptamin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "traumatic brain injury", 
            "glutamine", 
            "microdialysis", 
            "metabolism"
        ], 
        "lastchanged_date": "May 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "zip": "8006"
                }, 
                "name": "University Hospital Zurich"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Improvement of Therapy in Patients With Severe Traumatic Brain Injury: Differential Impact of Local and Systemic Changes and Routinely Applied Drugs", 
        "overall_official": {
            "affiliation": "University of Zurich", 
            "last_name": "John F Stover, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Switzerland: Swissmedic", 
                "Switzerland: Ethikkommission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "changes in plasma glutamine levels during and after infusion of alanyl-glutamine compared to baseline and intra-infusion values expressed in absolute (micromole/ liter) or relative (%) values", 
                "measure": "plasma glutamine levels", 
                "safety_issue": "No", 
                "time_frame": "2 to 7 days"
            }, 
            {
                "description": "changes in cerebral glutamine levels during and after infusion of alanyl-glutamine compared to baseline and intra-infusion values expressed in absolute (micromole/ liter) or relative (%) values", 
                "measure": "cerebral glutamine", 
                "safety_issue": "No", 
                "time_frame": "2 to 7 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02130674"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Zurich", 
            "investigator_full_name": "John Stover", 
            "investigator_title": "Prof. Dr. med.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "changes in cerebral lactate and lactate/pyruvate ratio reflecting cerebral energetic deficit during and after infusion of alanyl-glutamine compared to baseline and intra-infusion values expressed in absolute (millimole/ liter) or relative (%) values", 
                "measure": "cerebral lactate", 
                "safety_issue": "Yes", 
                "time_frame": "2 to 7 days"
            }, 
            {
                "description": "changes in lactate/pyruvate ratio reflecting cerebral energetic deficit during and after infusion of alanyl-glutamine compared to baseline and intra-infusion values expressed in absolute (millimole/ liter) or relative (%) values", 
                "measure": "cerebral lactate to pyruvate ratio", 
                "safety_issue": "Yes", 
                "time_frame": "2 to 7 days"
            }, 
            {
                "description": "changes in cerebral glutamate reflecting cerebral energetic deficit during and after infusion of alanyl-glutamine compared to baseline and intra-infusion values expressed in absolute (micromole/ liter) or relative (%) values", 
                "measure": "cerebral glutamate", 
                "safety_issue": "Yes", 
                "time_frame": "2 to 7 days"
            }, 
            {
                "description": "changes in intracranial pressure reflecting brain edema during and after infusion of alanyl-glutamine compared to baseline and intra-infusion values expressed in absolute (mm Hg) or relative (%) values", 
                "measure": "intracranial pressure", 
                "safety_issue": "Yes", 
                "time_frame": "2 to 7 days"
            }, 
            {
                "description": "changes in bispectral index EEG reflecting neuronal activation during and after infusion of alanyl-glutamine compared to baseline and intra-infusion values expressed in absolute or relative (%) values", 
                "measure": "bispectral index electroencephalography", 
                "safety_issue": "Yes", 
                "time_frame": "2 to 7 days"
            }
        ], 
        "source": "University of Zurich", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Swiss National Science Foundation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fresenius Kabi", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "University Hospital, Z\u00fcrich", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2005", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}